DDInter157 DDInter1376
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Azithromycin {u} (Compound) resembles {v} (Compound) Telithromycin
Azithromycin {u} (Compound) resembles {v} (Compound) Dirithromycin
Azithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Azithromycin {u} (Compound) binds {v} (Gene) CYP3A4
Azithromycin {u} (Compound) upregulates {v} (Gene) CDH3
Azithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Azithromycin {u} (Compound) downregulates {v} (Gene) TSTA3
Azithromycin {u} (Compound) causes {v} (Side Effect) Face oedema
Azithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Azithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Azithromycin (Compound) resembles Telithromycin (Compound)
Azithromycin (Compound) resembles Dirithromycin (Compound)
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Azithromycin (Compound) binds CYP3A4 (Gene)
Azithromycin (Compound) upregulates CDH3 (Gene)
Azithromycin (Compound) is included by Macrolides (Pharmacologic Class)
Azithromycin (Compound) downregulates TSTA3 (Gene)
Azithromycin (Compound) causes Face oedema (Side Effect)
Azithromycin may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli